Delisting risk
Citius Pharmaceuticals (CTXR)
Commercializes LYMPHIR for cutaneous T-cell lymphoma while developing infection, hemorrhoid, and cell-therapy programs.
$0.5731
Pre-market−0.01 (−2.02%)
At close$0.5849(+2.78%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Jan '25Feb '25May '25Aug '25Dec '25Feb '26May '26Aug '26
Reported−$1.75−$1.30−$1.27−$0.80−$0.44−$0.38−$0.95−$0.34
Estimate−$0.04−$1.25−$1.08−$0.24−$0.24$0.43−$0.28−$0.36
Surprise−4,275.0%−4.0%−17.6%−233.3%−83.6%−188.4%−238.4%+5.6%
RevenueReportedEstimate
Jan '25Feb '25May '25Aug '25Dec '25Feb '26May '26Aug '26
Reported$155.9K———$3.9M$3.9M$1.7M$1.5M
Estimate$7.1M$2.7M—$1.9M—$18.0M$10.2M$5.5M
Surprise−97.8%————−78.1%−83.7%−72.6%
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.36 | −$0.34 | +5.6% |
| May 2026 | −$0.28 | −$0.95 | −238.4% |
| Feb 2026 | $0.43 | −$0.38 | −188.4% |
| Dec 2025 | −$0.24 | −$0.44 | −83.6% |
The latest year is open to everyone — the 42 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Jan 2025 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Dec 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Dec 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Dec 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Dec 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Dec 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Dec 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Dec 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Dec 2015 | |||
| Aug 2015 | |||
| May 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | −$0.36 | −$0.34 | +5.6% | $5.5M | $1.5M | −72.6% | −25.6% |
| May 15, 2026 | −$0.28 | −$0.95 | −238.4% | $10.2M | $1.7M | −83.7% | −24.8% |
| Feb 13, 2026 | $0.43 | −$0.38 | −188.4% | $18.0M | $3.9M | −78.1% | −3.1% |
| Dec 25, 2025 | −$0.24 | −$0.44 | −83.6% | — | $3.9M | — | +5.0% |
The latest year is open to everyone — the 42 quarters behind it read with an account. Sign in | |||||||
| Aug 12, 2025 | |||||||
| May 14, 2025 | |||||||
| Feb 14, 2025 | |||||||
| Jan 3, 2025 | |||||||
| Aug 12, 2024 | |||||||
| May 14, 2024 | |||||||
| Feb 14, 2024 | |||||||
| Dec 29, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 12, 2023 | |||||||
| Feb 10, 2023 | |||||||
| Dec 22, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Feb 10, 2022 | |||||||
| Dec 15, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Dec 16, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 14, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Dec 16, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 15, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Dec 11, 2018 | |||||||
| Aug 15, 2018 | |||||||
| May 11, 2018 | |||||||
| Mar 20, 2018 | |||||||
| Dec 13, 2017 | |||||||
| Aug 14, 2017 | |||||||
| May 15, 2017 | |||||||
| Feb 14, 2017 | |||||||
| Dec 23, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 20, 2016 | |||||||
| Feb 12, 2016 | |||||||
| Dec 14, 2015 | |||||||
| Aug 12, 2015 | |||||||
| May 13, 2015 | |||||||